Pacific Biosciences of California (PACB) Stock Forecast & Price Target

PACB$1.96-0.01 -0.51%
Medical - DevicesValue StockHigh Quality
Compare
Market cap$611.98MEnterprise value$1.14BRevenue (TTM)$161.39MMarket position—

Score

63
Neutral
Value
72
Quality
66
Growth
50

Pacific Biosciences of California, Inc. price target

PACB
Low$1.35
Average$1.93
High$2.50
Upside vs current price-1.5%

The average target of $1.93 is -1.5% versus the current PACB price of $1.96.

Pacific Biosciences of California, Inc. analyst ratings

RatingAnalysts
Strong buy0
Buy4
Hold3
Sell0
Strong sell1
ConsensusHold

8 analysts cover PACB.

Pacific Biosciences of California, Inc. EPS and revenue estimates

Published annual figures for PACB on this page are 2026 EPS $-0.46, 2027 EPS $-0.45. Coverage under three analysts is omitted.

Fiscal yearEPS estimateRevenue estimate
2026$-0.46$158.40M
2027$-0.45$179.72M

Is Pacific Biosciences of California, Inc. a buy or sell?

Of the 8 analysts covering Pacific Biosciences of California, Inc., 4 rate it a buy (0 strong buy and 4 buy), 3 rate it a hold, and 1 rates it a sell (0 sell and 1 strong sell).

The PACB consensus label is Hold, beside 4 buy-side ratings and 1 sell-side ratings.

The average target of $1.93 implies -1.5% versus the current price of $1.96.

The PACB rating block is 8 published views with a Hold label. It does not tell you whether to buy or sell.

Reading the Pacific Biosciences of California, Inc. forecast

A wide spread is the story on PACB. Targets run from $1.35 to $2.50, with $1.93 as the average.

The gap from the $1.96 price to the PACB average is -1.5%.

the Pacific Biosciences of California, Inc. does not have a single rating camp: 4 of 8 analysts are on the buy side, 3 are at hold, and 1 is on the sell side, and the published consensus is Hold.

Month by month, the PACB average target is higher ($2.50) than the quarterly average ($1.93).

With 8 analysts on PACB, the average is a small sample.

Pacific Biosciences of California, Inc. forecast questions

What is the PACB price target?

The published range for PACB is $1.35 to $2.50, with an average of $1.93. That average is -1.5% versus the current price of $1.96.

Is Pacific Biosciences of California, Inc. a buy or sell?

Of the 8 analysts covering Pacific Biosciences of California, Inc., 4 rate it a buy, 3 rate it a hold, and 1 rates it a sell. The consensus is Hold, leaving PACB at 4 buy ratings, 3 holds, and 1 sells.

What is the EPS estimate for Pacific Biosciences of California, Inc.?

Analyst EPS estimates for Pacific Biosciences of California, Inc.: 2026 $-0.46, 2027 $-0.45.

What is the revenue estimate for Pacific Biosciences of California, Inc.?

Analyst revenue estimates for Pacific Biosciences of California, Inc.: 2026 $158.40M, 2027 $179.72M.

How many analysts cover PACB?

8 analysts cover PACB. Their consensus on PACB is Hold, across those 8.

PACB price $1.96 -0.01 -0.51%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener